New insights into a "friendly virus" that could pave the way for cutting-edge treatments for the potentially fatal superbug C ...

The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...

Known as phage therapy, it uses viruses to kill harmful bacteria in difficult-to-treat infections. Read more at ...

Returning to Boston this February, the Bacteriophage Therapy Summit is the only global platform for industry-dominated phage drug developers. Uniting 90+ Chief Executive Officers, Vice Presidents ...

Clostridioides difficile infection is a major healthcare-associated infection, causing significant morbidity and mortality, ...

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics ... is committed to advancing phage therapy with drug development ...

“New strategies, such as antibiotic stewardship programmes, novel therapeutics (such as bacteriophage therapy), and ongoing education for healthcare workers, are essential to control bacterial ...